Dr. Anthony H. Cincotta was a faculty member of Harvard Medical School and staff of Massachusetts General Hospital’s Department of Photomedicine during his clinical research career. Subsequently, he founded both Ergo Science Corp. and VeroScience, LLC to advance clinical therapies in diabetes and cancer. His 27+ successful years in clinical research and development generated scores of peer-reviewed publications in the fields of metabolism, chronobiology, and cancer research, as well as many U.S. and international patents. Along with his colleague, Dr. Meier, he is responsible for the invention of circadian timed bromocriptine-QR therapy (Cyclosetยฎ), the first-and-only sympatholytic dopamine agonist therapy for the treatment of type 2 diabetes.
